Literature DB >> 16885167

Proteinase-activated receptors, targets for kallikrein signaling.

Katerina Oikonomopoulou1, Kristina K Hansen, Mahmoud Saifeddine, Illa Tea, Michael Blaber, Sachiko I Blaber, Isobel Scarisbrick, Patricia Andrade-Gordon, Graeme S Cottrell, Nigel W Bunnett, Eleftherios P Diamandis, Morley D Hollenberg.   

Abstract

Serine proteinases like thrombin can signal to cells by the cleavage/activation of proteinase-activated receptors (PARs). Although thrombin is a recognized physiological activator of PAR(1) and PAR(4), the endogenous enzymes responsible for activating PAR(2) in settings other than the gastrointestinal system, where trypsin can activate PAR(2), are unknown. We tested the hypothesis that the human tissue kallikrein (hK) family of proteinases regulates PAR signaling by using the following: 1) a high pressure liquid chromatography (HPLC)-mass spectral analysis of the cleavage products yielded upon incubation of hK5, -6, and -14 with synthetic PAR N-terminal peptide sequences representing the cleavage/activation motifs of PAR(1), PAR(2), and PAR(4); 2) PAR-dependent calcium signaling responses in cells expressing PAR(1), PAR(2), and PAR(4) and in human platelets; 3) a vascular ring vasorelaxation assay; and 4) a PAR(4)-dependent rat and human platelet aggregation assay. We found that hK5, -6, and -14 all yielded PAR peptide cleavage sequences consistent with either receptor activation or inactivation/disarming. Furthermore, hK14 was able to activate PAR(1), PAR(2), and PAR(4) and to disarm/inhibit PAR(1). Although hK5 and -6 were also able to activate PAR(2), they failed to cause PAR(4)-dependent aggregation of rat and human platelets, although hK14 did. Furthermore, the relative potencies and maximum effects of hK14 and -6 to activate PAR(2)-mediated calcium signaling differed. Our data indicate that in physiological settings, hKs may represent important endogenous regulators of the PARs and that different hKs can have differential actions on PAR(1), PAR(2), and PAR(4).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885167     DOI: 10.1074/jbc.M513138200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  87 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

2.  Kallikrein 6 is a novel molecular trigger of reactive astrogliosis.

Authors:  Isobel A Scarisbrick; Maja Radulovic; Joshua E Burda; Nadya Larson; Sachiko I Blaber; Caterina Giannini; Michael Blaber; Alexander G Vandell
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

Review 3.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

Review 4.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

Review 5.  Why thrombin PAR1 receptors are important to the cardiac surgical patient.

Authors:  Clive Landis
Journal:  J Extra Corpor Technol       Date:  2007-12

Review 6.  Gastrointestinal roles for proteinase-activated receptors in health and disease.

Authors:  A Kawabata; M Matsunami; F Sekiguchi
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

7.  Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model.

Authors:  Jianzhong An; Magarya S Waitara; Michelle Bordas; Vidhyalakshmi Arumugam; Raymond G Hoffmann; Brian G Petrich; Uma Sinha; Paula E North; Rashmi Sood
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

8.  Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma.

Authors:  Spyridon Christodoulou; Dimitra K Alexopoulou; Christos K Kontos; Andreas Scorilas; Iordanis N Papadopoulos
Journal:  Tumour Biol       Date:  2014-01-16

9.  Evaluation of antibodies directed against human protease-activated receptor-2.

Authors:  Mark N Adams; Charles N Pagel; Eleanor J Mackie; John D Hooper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-31       Impact factor: 3.000

10.  Activation of PAR(2) receptors sensitizes primary afferents and causes leukocyte rolling and adherence in the rat knee joint.

Authors:  F A Russell; N Schuelert; V E Veldhoen; M D Hollenberg; J J McDougall
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.